MarzAA Reduced Bleed Frequency in Certain Male Patients

MarzAA Reduced Bleed Frequency in Certain Male Patients

304662

MarzAA Reduced Bleed Frequency in Certain Male Patients

Preventive treatment with marzeptacog alfa activated (MarzAA) can reduce bleed frequency substantially in men with hemophilia A or B who developed inhibitors to conventional replacement therapies, according to data from a Phase 2 clinical trial. The findings were reported in the study, “Subcutaneous engineered factor VIIa marzeptacog alfa (activated) in hemophilia with inhibitors: Phase 2 trial of pharmacokinetics, pharmacodynamics, efficacy, and safety,” published in the journal Research and Practice in Thrombosis and Haemostasis. Hemophilia is…

You must be logged in to read/download the full post.